Earnings ·
Structure Therapeutics Inc. reported financial results for the second quarter ended June 30, 2026, and announced that…
GPCRStructure Therapeutics Inc.
Structure Therapeutics Inc. reported financial results for the second quarter ended June 30, 2026, and announced that the first patients have been dosed in its Phase 3 ACCOMPLISH program evaluating aleniglipron for chronic weight management. The company appointed John Berrios as Chief Commercial Officer. R&D expenses increased to $100.1 million from $54.7 million in the prior year period, resulting in a net loss of $106.2 million compared to $61.7 million previously. Cash, cash equivalents, and short-term investments totaled $1.3 billion as of June 30, 2026, which management expects will fund operations through 2028. Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for metabolic diseases.